Dr. Thomas O. Carpenter, MD
Pediatric Endocrinology (Pediatric Endocrinology Physician)
At a glance
- In the NPI registry since
- 2005
Licensed in Connecticut since 1986, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
CT license 027051 (first issued 1986; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 7 payments worth $7,929 in total to this clinician.
| Kyowa Kirin, Inc. | $6,060 |
|---|---|
| BioMarin Pharmaceutical Inc. | $1,369 |
| Mirum Pharmaceuticals, Inc. | $500 |
| Consulting Fee | $7,929 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kyowa Kirin, Inc. Jun 5, 2025 | Consulting Fee | $3,030 |
| Kyowa Kirin, Inc. Nov 6, 2025 | Consulting Fee | $1,515 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| Kyowa Kirin, Inc. Mar 13, 2025 | Consulting Fee | $505 |
| Kyowa Kirin, Inc. Nov 6, 2025 | Consulting Fee | $505 |
| Kyowa Kirin, Inc. Dec 18, 2025 | Consulting Fee | $505 |
| Mirum Pharmaceuticals, Inc. May 8, 2025 | Consulting Fee | $500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $1,354,188 in research payments for these studies, mostly to the institutions running them.
- X-linked Hypophosphatemia Disease Monitoring Program
Ultragenyx Pharmaceutical Inc. · Active, not recruiting · NCT03651505 - Study name not reported
Ultragenyx Pharmaceutical Inc. - Study name not reported
Ultragenyx Pharmaceutical Inc. - Tumor-induced Osteomalacia Disease Monitoring Program
Ultragenyx Pharmaceutical Inc. · Active, not recruiting · NCT04783428 - Study name not reported
Ultragenyx Pharmaceutical Inc. - A Registry for Participants With Chronic Hypoparathyroidism
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT01922440
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.